Q3-FY26 · Punit Kumar Rasara
We are believing that result would be much better than 370 to 380 CR.
ANLONHEALTHCARE / language trends
Read confidence between the lines.
Anlon Healthcare · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · Punit Kumar Rasara
We are the only Indian manufacturer of loxoprofen and we'll have the first-mover advantage with monopoly in pain management.
Q3-FY26 · Punit Kumar Rasara
In healthcare segment all the pharma company in India are almost at the same level... everyone is having equal opportunities.